SS
VERV

Steve Schonfeld’s Verve Therapeutics VERV Stock Holding History

Steve Schonfeld’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-176,281
Closed -$1.98M – 2611
2025
Q2 		$1.98M Sell
176,281
-2,747,137
-94% -$15.7M 0.01% 997
2025
Q1 		$13.4M Sell
2,923,418
-865,961
-23% -$5.8M 0.08% 248
2024
Q4 		$21.4M Buy
3,789,379
+1,382,176
+57% +$7.8M 0.12% 139
2024
Q3 		$11.7M Buy
+2,407,203
New +$14M 0.08% 256
2023
Q1 		– Sell
-51,640
Closed -$999K – 2684
2022
Q4 		$999K Buy
51,640
+28,627
+124% +$758K 0.01% 1151
2022
Q3 		$790K Sell
23,013
-2,368
-9% -$75.6K 0.01% 1445
2022
Q2 		$388K Buy
+25,381
New +$393K ﹤0.01% 1509

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Steve Schonfeld's VERV Position: Q3 2025 in Review

Steve Schonfeld sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 176,281 shares — an estimated $1.98M sold.

Steve Schonfeld first reported a position in VERV in Q2 2022 and held it in 7 quarters. The position peaked at $21.4M in Q4 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Steve Schonfeld reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Steve Schonfeld sold 176,281 Verve Therapeutics shares in Q3 2025, an estimated $1.98M.
  • Steve Schonfeld first reported a position in Verve Therapeutics in Q2 2022 and held it in 7 quarters.
  • Steve Schonfeld's Verve Therapeutics position peaked at $21.4M in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.